Benzene and Acute Myeloid Leukemia: A Clinical Evidence Review

From General Health Information to Occupational Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of environmental risks. Within this broad context, discussions of chemical exposures and their potential health consequences have typically emphasized universal precautions and population-level awareness. This heritage provides a necessary baseline for recognizing that certain substances, when encountered in everyday settings, may carry latent hazards. However, the translation of such general knowledge into specific, actionable guidance often remains incomplete, particularly when addressing the conditions under which exposure becomes clinically significant. As we pivot from this broad informational landscape, a more focused examination is warranted—one that moves beyond generic health advisories to consider the realities of occupational environments. In industrial and manufacturing settings, the nature of exposure to chemical agents differs markedly from ambient or incidental contact. Here, the frequency, duration, and concentration of exposure can reach levels that demand rigorous scrutiny. This transition from general health context to occupational exposure concern is essential for understanding how routine workplace conditions may intersect with specific disease risks, without yet invoking mechanistic explanations. The following review therefore narrows its lens to the clinical evidence surrounding benzene exposure and its established association with acute myeloid leukemia, grounding the discussion in the practical realities of mass production environments.

Benzene as a Myelotoxin and Risk Factor for AML

Benzene is a well-established myelotoxin and recognized risk factor for the development of acute myeloid leukemia (AML). Chronic exposure to benzene can augment the risk for the onset of AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013). Previous studies have established a causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681). Additionally, a meta-analysis of 25 studies found that benzene exposure was associated with an increased risk of AML in children, with an odds ratio of 1.22 (95% CI: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753). The clinical presentation of AML typically includes symptoms related to bone marrow failure, such as fatigue, pallor, infection, and bleeding, along with signs of extramedullary involvement. Diagnosis is confirmed by bone marrow biopsy showing at least 20% blasts, with cytogenetic and molecular profiling guiding subclassification and treatment. Benzene-induced AML often arises after a latency period that can range from several months to decades following exposure, depending on intensity and duration.

Mechanistic Pathways and Risk Assessment

The mechanistic pathways linking benzene to AML involve multiple key events. Benzene is metabolized in the liver to reactive intermediates, such as hydroquinone and benzoquinone, which cause genotoxic damage, oxidative stress, and inflammation (https://pubmed.ncbi.nlm.nih.gov/34069279). These metabolites induce chromosomal aberrations, including translocations and deletions, in hematopoietic stem cells. The mode of action for AML development includes earlier key events observable as hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013). Benzene also provokes immunosuppression, further promoting leukemogenesis (https://pubmed.ncbi.nlm.nih.gov/34069279). Epigenetic alterations, such as altered gene expression, are increasingly recognized as contributing factors beyond genetic changes alone (https://pubmed.ncbi.nlm.nih.gov/34069279). Risk assessment for benzene-induced AML can be improved by integrating data from human epidemiologic studies, human biomarker studies, and experimental animal data. A linear meta-regression model best predicted AML risks when combining six human AML studies, three human leukemia studies, ten human biomarker studies, and four experimental animal studies (https://pubmed.ncbi.nlm.nih.gov/34906966). This approach helps estimate the exposure-response curve across a range of benzene concentrations, particularly where data are sparse.

Adequacy of Warnings and Clinical Implications

Regarding adequacy of warnings, the evidence indicates that benzene is acknowledged as a myelotoxin and that its carcinogenic ability has been reported (https://pubmed.ncbi.nlm.nih.gov/34069279). Occupational exposure limits have been set in many jurisdictions, but the risk at lower levels remains a concern. The Swiss National Cohort study examined occupational benzene exposure and mortality from lymphohaematopoietic cancers, applying a quantitative benzene job-exposure matrix to census-reported occupations (https://pubmed.ncbi.nlm.nih.gov/38727681). This underscores the need for ongoing surveillance and risk communication for workers and the public. For causation-related considerations, affected patients should be evaluated for a history of benzene exposure, including occupational, environmental, or consumer product sources. The timeline between exposure and documented harm can vary, but early key events such as hematotoxicity and genetic toxicity can be detected in peripheral blood before AML develops (https://pubmed.ncbi.nlm.nih.gov/33429013). Prevention of these early events would lead to prevention of the apical adverse outcomes, including morbidity and mortality from AML and myelodysplastic syndromes (https://pubmed.ncbi.nlm.nih.gov/33429013). Clinicians should consider benzene exposure as a potential contributing factor in AML cases, particularly when other risk factors are absent. In summary, the evidence strongly supports a causal link between benzene exposure and AML, with multiple mechanistic pathways and a consistent exposure-response relationship. Adequate warnings and risk mitigation strategies are essential to reduce the burden of benzene-induced leukemia.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the evidence linking benzene to acute myeloid leukemia?

Benzene is a well-established myelotoxin and recognized risk factor for AML. Chronic exposure increases risk for AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279). Occupational exposure at levels of 10 ppm or more is associated with increased AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013). A meta-analysis of 25 studies found an increased risk of AML in children per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753).

How does benzene cause acute myeloid leukemia?

Benzene is metabolized in the liver to reactive intermediates like hydroquinone and benzoquinone, causing genotoxic damage, oxidative stress, and inflammation (https://pubmed.ncbi.nlm.nih.gov/34069279). These metabolites induce chromosomal aberrations in hematopoietic stem cells. The mode of action includes hematotoxicity and genetic toxicity observable in peripheral blood (https://pubmed.ncbi.nlm.nih.gov/33429013). Benzene also causes immunosuppression and epigenetic alterations (https://pubmed.ncbi.nlm.nih.gov/34069279).

What are the clinical implications for patients with AML and benzene exposure?

Patients should be evaluated for a history of benzene exposure from occupational, environmental, or consumer product sources. Early key events like hematotoxicity can be detected before AML develops (https://pubmed.ncbi.nlm.nih.gov/33429013). Clinicians should consider benzene as a contributing factor, especially when other risk factors are absent. Prevention of early events can prevent progression to AML (https://pubmed.ncbi.nlm.nih.gov/33429013).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.